(Fighting New Coronary Pneumonia) The European Union Announces Orders for 160 million doses of Modena's New Coronary Vaccine
China News Agency, Brussels, November 24 (Reporter De Yongjian) After the US biotechnology company Modena reported that the new crown vaccine developed by the company was effective at 94.5%, the European Union announced on the 24th that it had reached an agreement with Modena to order 1.6 100 million doses of Modena's new crown vaccine.
The picture shows Von Delane reading out the order statement in a video format.
China News Agency issued photos for EU
The President of the European Commission von der Lein read out the order statement via video on the same day.
She said that this is the sixth COVID-19 vaccine order agreement between the EU and pharmaceutical companies, and the EU is still working to reach the seventh COVID-19 vaccine order agreement.
Von der Lein did not disclose the price of the vaccine agreed between the EU and Modena. He only praised the clinical trials for showing the effectiveness of the Modena new crown vaccine. However, like other new crown vaccines, it can only be approved by the European Medicines Agency before it can be submitted to the EU. Market launch.
Like the new crown vaccine jointly developed by the German biotech company and the American Pfizer Pharmaceutical Co., Ltd., the Modena new crown vaccine also uses messenger ribonucleic acid technology.
On November 16, Modena announced that its vaccine has an effectiveness of 94.5%, and does not require ultra-low temperature storage. It can be stored at a temperature of 2 to 8 degrees Celsius (generally refrigerator cold room temperature) for 30 days, and at a temperature of minus 20 degrees Celsius Keep for 6 months.
The picture shows Von Delane reading out the order statement in a video format.
China News Agency issued photos for EU
After announcing the order for Modena's new crown vaccine on the 24th, Von der Lein said that the EU's goal is to include the most promising new crown vaccine currently being developed and "build a world's most comprehensive combination of new crown vaccines"; once the vaccine is approved for use , The European Union will distribute vaccines to each member country at the same time, under the same conditions, and in proportion to the population.
According to data, at the end of August this year, the European Union and AstraZeneca Pharmaceuticals of the United Kingdom reached the first new crown vaccine order agreement, and then it has cooperated with Sanofi and GlaxoSmithKline to develop vaccines, German Biotech and Pfizer Pharmaceuticals of the United States. And Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson in the United States, and CureVac in Germany have reached an order agreement, including the 160 million doses of vaccine ordered on the 24th, so far the EU has ordered nearly 2 billion doses of new crown vaccine (including additional vaccines) On average, each citizen of an EU member state can get about 4 doses of vaccine.
(Finish)